KBC Group NV Makes New $49,000 Investment in Evolus, Inc. (NASDAQ:EOLS)

KBC Group NV acquired a new stake in Evolus, Inc. (NASDAQ:EOLS) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 4,451 shares of the company’s stock, valued at approximately $49,000.

Other institutional investors have also modified their holdings of the company. AQR Capital Management LLC boosted its stake in Evolus by 33.3% during the 2nd quarter. AQR Capital Management LLC now owns 72,007 shares of the company’s stock worth $781,000 after purchasing an additional 17,971 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in Evolus by 36.3% during the second quarter. The Manufacturers Life Insurance Company now owns 21,825 shares of the company’s stock worth $237,000 after purchasing an additional 5,808 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Evolus during the third quarter worth about $623,000. Creative Planning grew its stake in shares of Evolus by 23.7% in the third quarter. Creative Planning now owns 15,451 shares of the company’s stock worth $250,000 after acquiring an additional 2,963 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its stake in Evolus by 0.9% in the third quarter. Assenagon Asset Management S.A. now owns 955,555 shares of the company’s stock worth $15,480,000 after acquiring an additional 8,452 shares during the last quarter. Institutional investors and hedge funds own 90.69% of the company’s stock.

Analyst Ratings Changes

EOLS has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and issued a $27.00 price objective on shares of Evolus in a research note on Wednesday, January 22nd. Needham & Company LLC restated a “buy” rating and set a $22.00 target price on shares of Evolus in a research report on Tuesday, January 21st. Finally, Barclays lifted their target price on shares of Evolus from $20.00 to $22.00 and gave the stock an “overweight” rating in a research report on Monday, January 27th.

Evolus Stock Performance

Evolus stock opened at $13.11 on Tuesday. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The firm has a market capitalization of $830.14 million, a P/E ratio of -14.41 and a beta of 1.33. The stock has a fifty day moving average price of $11.95 and a 200 day moving average price of $13.94. Evolus, Inc. has a 52 week low of $9.25 and a 52 week high of $17.82.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.